Cocaine HCl
(Cocaine)ApprovedSmall molecule
Cocaine is a local anesthetic used medically to numb tissues during certain surgical procedures, particularly in nasal and ear surgery. It also constricts blood vessels, which helps reduce bleeding during these procedures.[2] Cocaine HCl is currently approved and in use across 1 indication[4].[1]
Cocaine HCl is one of 22 small molecule programs targeting Allergic Disease. It is currently in Approved.
1
Indications
29
Total Trials
1
Active Trials
21
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
12
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
21 competitors in Allergic Disease
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Foradil
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Allegra
CChattem
Approved
Claritin
PPerrigo Company
Approved
Benadryl
PParkedale
Approved
Taxotere
AAvyxa
Approved
Pulmicort
SSalix
Approved
Celestone
SSchering-Plough
Approved
Sudafed
KKenvue Brands
Approved
Xyzal
CChattem
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
AIN8 trials
Interaction3 trials
Drug3 trials
Cocaine Abuse3 trials
9 more indications
Cocaine Dependence2 trials
Complementary Combination Therapy for Cocaine Dependence
Completed·—·Phase 1·NCT02538744·45 enrolled
Anesthesia1 trial
Cocaine Use Disorder1 trial
ENT Disorder1 trial
Regulatory
FDA Approval Timeline[5]
Dec 14, 2017
GOPRELTO
NDA NDA209963
Jan 10, 2020
NUMBRINO
NDA NDA209575
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cocaine HCl drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cocaine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]